Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05684588 Active, not recruiting - Osteonecrosis Clinical Trials

Post-COVID-19 Sequelae: Osteonecrosis of Femoral Head

Covid-ON
Start date: November 15, 2021
Phase: N/A
Study type: Interventional

During the most recent pandemy COVID-19, various advises concerning complications following high corticosteroid doses administration were pubblished in 2020. However, evidence is lacking about the incidence of Non-traumatic osteonecrosis of the femoral head (ONFH) in patients experiencing COVID-19. The aim of the present proposal is to obtain a quantitative estimation of ONFH cases among patients previoulsy hospitalized and treated for COVID-19 at ASST-Papa Giovanni XXIII.

NCT ID: NCT05683600 Active, not recruiting - COVID-19 Clinical Trials

Efficacy and Safety of LYB001 as Booster Vaccination in Adults 18 Years of Age or Older

Start date: December 29, 2022
Phase: Phase 3
Study type: Interventional

This is an international multicenter clinical trial, which is planned to be conducted in several research centers in China and Pakistan. A randomized, double-blind, placebo-controlled design will be conducted to evaluate the efficacy, safety of LYB001 against COVID-19 as a booster dose in China.

NCT ID: NCT05683353 Active, not recruiting - Clinical trials for SARS-CoV-2 Infection

Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors

Start date: December 14, 2022
Phase:
Study type: Observational

The goal of this observational study is to compare the immune function and infection mechanism of patients with hematologic tumors and those people without underlying diseases after infection with SARS-CoV-2. Clinical characteristics, treatment options and responses will be collected. Peripheral blood will be collected from patients with hematologic tumors infected with SARS-CoV-2 and those people without underlying diseases infected with SARS-CoV-2.

NCT ID: NCT05679466 Active, not recruiting - Clinical trials for Prevention of COVID-19 Caused by SARS-CoV-2

An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older

Start date: December 27, 2022
Phase: Early Phase 1
Study type: Interventional

Study Objective(s) To evaluate the safety, immunogenicity and protective efficacy of 1 dose of ReCOV in participants who have received 2 or 3 doses of inactivated SARS-CoV-2 vaccination in Chinese adults aged 18 years and older. Primary objective To demonstrate the safety within 30 days after booster dose. Secondary objective(s) To evaluate the immunogenicity after booster dose. To demonstrate the safety within 6 months after booster dose. To evaluate the protective efficacy of RT-PCR-confirmed SARS-CoV-2 infection and COVID-19 after booster dose. Indications:Prevention of COVID-19 caused by SARS-CoV-2 Population:Participants aged 18 years and older who completed 2 or 3 doses vaccination of inactivated COVID-19 vaccines and whose last dose was given 6-18 months, of which the elderly aged 60 years and older account for about 10% to 15%. Sample Size:Approximately 3,300 participants

NCT ID: NCT05667714 Active, not recruiting - COVID-19 Clinical Trials

Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 People

Start date: November 26, 2022
Phase: N/A
Study type: Interventional

This is a randomized, single-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of SA58 nasal spray in close contact with COVID-19 people.

NCT ID: NCT05664932 Active, not recruiting - COVID-19 Clinical Trials

Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above

Start date: December 28, 2022
Phase: Phase 3
Study type: Interventional

A total of 1200 people aged 18 years and older who have completed two or three-dose inactivated COVID-19 vaccine for 6-18 months will be recruited in this study. Subjects will be received 1 dose at day 0 as a booster vaccination.Immunogenicity and safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 will be evaluated.

NCT ID: NCT05664919 Active, not recruiting - COVID-19 Clinical Trials

Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations

Start date: October 30, 2022
Phase: N/A
Study type: Interventional

This is an open, blank controlled clinical trial to evaluate the efficacy and safety of SA58 nasal spray in the prevention COVID-19 infection among health care workers at high risk of SARS-CoV-2 infection.

NCT ID: NCT05656508 Active, not recruiting - COVID-19 Vaccine Clinical Trials

ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine

Start date: April 20, 2022
Phase: Phase 1
Study type: Interventional

The objective of this clinical trial is to test a new vaccine against SARS-CoV-2 (ARVAC-CG) in healthy adult volunteers, previously vaccinated against the SARS-CoV-2 virus. The main questions it aims to answer are: - What is the safety and tolerability profile of the two-dose schedule of this new vaccine? - What is the immune response after each dose of vaccine Participants will receive two doses of the study vaccine 28 days apart. They will be required to complete a total of 7 safety and immunogenicity follow-up visits over a 1-year period.

NCT ID: NCT05650957 Active, not recruiting - COVID-19 Clinical Trials

Epidemiology, Ventilation Management and Outcomes in Patients With ARDS Due to COVID-19 Versus ARDS Due to Other Pulmonary Infections

Start date: August 1, 2022
Phase:
Study type: Observational

This study aims to compare epidemiology, management of invasive ventilation and outcomes in critically ill patients with COVID-19 ARDS and ARDS from another pulmonary infection. We will use individual patient data from four recently published large observational COVID-9 studies, including the 'Practice of VENTilation in COVID-19 patients' (PRoVENT-COVID) study, the 'Epidemiology of COVID-19 patients in the ICU' (EPICCoV) study, the 'SATI-COVID-19 - Clinical Characteristics and Outcomes of Patients With COVID-19 on Mechanical Ventilation in Argentina: a Prospective, Multicenter Cohort Study' and the CIBERESUCICOVID - Personalized Risk and Prognosis Factors and Follow-up at One Year of the Patients Hospitalized in the Spanish Intensive Care Units Infected with COVID -19' study. We will use the individual patient data from ARDS patients with another pulmonary infection from the 'LUNG -SAFE - Large Observational Study to UNderstand the Global Impact of Severe Acute Respiratory FailurE' study and the 'ERICC - Epidemiology of Respiratory Insufficiency in Critical Care' study.

NCT ID: NCT05638932 Active, not recruiting - COVID-19 Clinical Trials

Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments

Start date: June 16, 2020
Phase:
Study type: Observational

To apply and compare two different methodological approaches (one applying diagnostics steps and contingencies and the other not) to the illustrative example described below: Illustrative Example - Objective I aims to characterize the risk of inpatient mortality [Primary Outcome] and progression to invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) [Secondary Outcome] up to 28 days after interleukin-6 receptor inhibitors (IL6Ri) or janus kinase inhibitor (JAKi) initiation among patients hospitalized with COVID-19 who initiate a corticosteroid of interest and require supplemental oxygen / non-invasive ventilation / high flow oxygen (O2/NIV/HFO) (but not IMV/ECMO). Illustrative Example - Objective II aims to characterize the risk of inpatient mortality [Primary Outcome] up to 28 days after IL6Ri or JAKi initiation among patients admitted to the ICU at hospital admission with COVID-19 who initiate a CSI and require IMV/ECMO. Hazard ratios (HR) and corresponding 95% confidence intervals (CI) will be estimated and reported for all outcome risks in Illustrative Example objectives.